Friday, 27 April 2018

Ethnopharmacological approaches in mood and anxiety disorders. The relevance of the oxidative stress status

Simplice Harquin Foyet / Ioana-Miruna Balmus / Ngatanko Abaïssou Hervé Hervé / Asongalem Acha Emmanuel / Samson Guenne / Martin Kiendrebéogo / Alin Ciobica Published Online: 2017-03-09 | DOI: 30,00 € / $42.00 / £23.00 Get Access to Full Text Abstract Neurodegenerative diseases and psychiatric disorders are one of the most important pathologies that lead to increased morbidity in populations. Both mood and anxiety disorders include mental disorders not caused by detectable organic abnormalities of the brain. At the molecular level, affective spectrum symptomatology is due to neurotransmitter dysregulation including receptor or transporter impairments and also due to faulty intracellular signaling that generally leads to impaired neurotransmission. Also, recent studies have shown the relationship between oxidative stress and the development of affective disorders. Since classical medication can cause major side effects and alternative approaches tend to be more and more trusted, it seems that plant extracts-based complementary therapies may offer superior yielding and safety compared to traditional medication. Keywords: antioxidant enzymes; anxiety; depression; panic disorder; plant extracts References 1. Mohamed I, Shuid A, Borhanuddin H, Fozi N. The application of phytomedicine in modern drug development. Int J Herb Plant Med. 2012;1:1–9.Google Scholar 2. Payyappallimana U. Role of traditional medicine in primary health care: an overview of perspectives and challenges. Yokohama J Soc Sci. 2010;14:57–77.Google Scholar 3. Pilania M, Bairwa M, Kumar N, Khanna P, Kurana H. Elderly depression in India: an emerging public health challenge. Australas Med J. 2013;6:107–111.CrossrefGoogle Scholar 4. World Health Organization. Neurological disorders affect millions globally report. Brussels/Geneva: World Health Organization, 2007.Google Scholar 5. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007;62:617–627.Google Scholar 6. Sobocki P, Jönsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ. 2006;9:87–98.Google Scholar 7. Sylvie DD, Pieme CA, Biapa PC, Penlap BV. Comparison of in vitro antioxidant properties of extracts from three plants used for medical purpose in Cameroon: Acalypha racemosa, Garcinia lucida and Hymenocardia lyrata. Asian Pac J Trop Biomed. 2014;4–2 . S625–S632.CrossrefGoogle Scholar 8. Xu Y, Wang C, Klabnik JJ, O’Donnell JM. Novel therapeutic targets in depression and anxiety: antioxidants as a candidate treatment. Cur Neuropharmacol. 2014;12:108–119.Google Scholar 9. Trebatická J, Ďuračková Z. Psychiatric disorders and polyphenols: Can they be helpful in therapy?. Oxid Med Cell Longev. 2005;248529.Google Scholar 10. Halliwell B, Lee CY. Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Antioxid Redox Signaling. 2010;13:145–156.Google Scholar 11. Halliwell B. Free radicals and antioxidants – quo vadis?. Trends Pharmacol Sci. 2011;32:125–130.CrossrefGoogle Scholar 12. Hovatta I, Juhila J, Donner J. Oxidative stress in anxiety and comorbid disorders. Neurosci Res. 2010;68:261–27.CrossrefGoogle Scholar 13. Akiskal HS. Mood disorders: clinical features. In: Kaplan HI, Sadock BJ, Sadock VA, editors. Kaplan & Sadock’s comprehensive textbook of psychiatry. Philadelphia, PA: Wolters Kluwer: Lippincott Williams & Wilkins, 2004:1.Google Scholar 14. Wilhelm K, Roy K. Gender differences in depression risk and coping factors in a clinical sample. Acta Psychiatr Scandinav. 2003;106:45–53.CrossrefGoogle Scholar 15. Fišar K, Hroudová J, Raboch J. Neurotransmission in mood disorders. In: Juruena MF, editors. Clinical research and treatment approaches to affective disorders. Rijeka: InTechOpen, 2012:47.Google Scholar 16. Evans DL, Charney DS, Lewis IL, Golden RN, Gorman JM, Krishnan KR, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry. 2005;58:175–189.CrossrefGoogle Scholar 17. Li X, Frye MA, Shelton RC. Mood disorders. Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacol Rev. 2012;37:77–101.CrossrefGoogle Scholar 18. Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev Neurosci. 2003;14:609–625.CrossrefGoogle Scholar 19. Angst J, Ajdacic-Gross V, Rössler W. Classification of mood disorders. Psychiatr Pol. 2015;49:663–671.CrossrefGoogle Scholar 20. Chang CC, Jou SH, Lin TT, Lai TT, Liu CS. Mitochondria DNA change and oxidative damage in clinically stable patients with major depressive disorder. Plos One. 2015;10:0125855.Google Scholar 21. Vaváková M, Ďuračková Z, Trebatická J. Markers of oxidative stress and neuroprogression in depression disorder. Oxid Med Cell Longev 2015 . ID 898393.Google Scholar 22. Silva MCC, De Sousa CNS, Gomes PXL, De Oliveira GV, Araújo FYR, Ximenes NC, et al. Evidence for protective effect of lipoic acid and desvenlafaxine on oxidative stress in a model depression in mice. Prog Neuro-Psychopharmacol Biol Psych. 2016;64:142–148.CrossrefGoogle Scholar 23. Fuchs E, Flügge G. Adult neuroplasticity: more than 40 years of research. Neural Plast. 2014;541870.Google Scholar 24. Ditzen C, Jastorff AM, Keßler MS, Bunck M, Teplytska L, Erhardt A, et al. Protein biomarkers in a mouse model of extremes in trait anxiety. Mol Cell Proteomics. 2006;5:1914–1920.CrossrefGoogle Scholar 25. Siwek M, Sowa-Kuæma M, Dudek D, Styczeñ K, Szewczyk B, Kotarska K, et al. Oxidative stress markers in affective disorders. Pharmacol Rep. 2013;65:1558–1571.CrossrefGoogle Scholar 26. Sarris J, McIntyre E, Camfield DA. Plant-based medicines for anxiety disorders, Part 1: a review of preclinical studies. CNS Drugs. 2013;27:207–219.Google Scholar 27. Ďuračková Z. Some current insights into oxidative stress. Physiol Res. 2010;59:459–469.Google Scholar 28. Salim S. Oxidative stress and psychological disorders. Cur Neuropharmacol. 2014;12:140–147.Google Scholar 29. Luca M, Luca A, Calandra C. Accelerated aging in major depression: the role of nitro-oxidative stress. Oxid Med Cell Longev 2013 . ID 230797.Google Scholar 30. Gautam M, Agrawal M, Gautam M, Sharma A, Gautam A, Gautam M. Role of antioxidants in generalised anxiety disorder and depression. Indian J Psychiatry. 2012;54:244–247.CrossrefGoogle Scholar 31. Bulut M, Selek S, Bez Y, Karababa YA, Kaya MC, et al. Reduced PON1 enzymatic activity and increased lipid hydroperoxide levels that point out oxidative stress in generalized anxiety disorder. J Affect Disord. 2013;150:829–833.Google Scholar 32. Bouayed J, Rammal H, Younos C, Soulimani R. Positive correlation between peripheral blood granulocyte oxidative status and level of anxiety in mice. Eur J Pharmacol. 2007;564:146–149.CrossrefGoogle Scholar 33. Masood A, Nadeem A, Mustafa SJ, O’Donnell JM. Reversal of oxidative stress-induced anxiety by inhibition of phosphodiesterase-2 in mice. J Pharmacol Exp Ther. 2008;326:369–379.CrossrefGoogle Scholar 34. Ranjana SK, Reena N, Deepti P, Shruti K, Hari KD. Markers of oxidative stress in generalized anxiety psychiatric disorder: therapeutic implications. J Stress Physiol Biochem. 2012;8:32–38.Google Scholar 35. Hassan W, Silva CEB, Mohammadzai IU, Da Rocha JTB, Landeira-Fernandez J. Association of oxidative stress to the genesis of anxiety: implications for possible therapeutic interventions. Cur Neuropharmacol. 2014;12:120–139.Google Scholar 36. Berry A, Capone F, Giorgio M, Pelicci PG, De Kloet ER, Alleva E, et al. Deletion of the life span determinant p66Shc prevents age-dependent increases in emotionality and pain sensitivity in mice. Exp Gerontol. 2007;42:37–45.CrossrefGoogle Scholar 37. Ersoy M, Salek K, Celik H, Erel O, Kaya MC, Savas HA. Role of oxidative and antioxidative parameters in ethiopathogenesis and prognosis of panic disorder. Int J Neurosci. 2008;118:1025–1037.CrossrefGoogle Scholar 38. Cengiz M, Bayoglu B, Alansal NO, Cengiz S, Dirican A, Kocabasoglu N. Pro198Leu polymorphism in the oxidative stress gene, glutathione peroxidase-1, is associated with a gender-specific risk for panic disorder. Int J Psychiatry Clin Pract. 2015;2:1–7.Google Scholar 39. Lissemore JI, Leyton M, Gravel P, Sookman D, Nordahl TE, Benkelfat C PET and SPECT in Psychiatry. In: Rajo D, et al., editors. OCD: Serotonergic mechanisms. Berlin: Springer, 2014:433–450.Google Scholar 40. Orhan N, Kucukali CI, Cakir U, Seker N, Aydin M. Genetic variants in nuclearencoded mitochondrial proteins are associated with oxidative stress in obsessive compulsive disorders. J Psychiat Res. 2012;46:212e8.CrossrefGoogle Scholar 41. Behl A, Swami G, Sircar SS, Bhatia MS, Banerjee BD. Relationship of possible stress related biochemical markers to oxidative/antioxidative status in obsessive compulsive disorder. Neuropsychobiology. 2010;61:210e4.CrossrefGoogle Scholar 42. Selek S, Herken H, Bulut M, Ceylan MF, Celik H, Savas HA, et al. Oxidative imbalance in obsessive compulsive disorder patients: a total evaluation of oxidantantioxidant status. Prog Neuro-Psychopharmacol Biol Psych. 2008;32:487e91.CrossrefGoogle Scholar 43. Kandemir H, Abuhandan M, Aksoy N, Savik E, Kaya C. Oxidative imbalance in child and adolescent patients with obsessive compulsive disorder. J Psychiatr Res. 2013;47:1831e1834.CrossrefGoogle Scholar 44. Krolow R, Arcego DM, Noschang C, Weis SN, Dalmaz C. Oxidative imbalance and anxiety disorders. Cur Neuropharmacol. 2014;12:193–204.Google Scholar 45. Martin A, Chalder T, Rief W, Braehler E. The relationship between chronic fatigue and somatization syndrome: a general population survey. J Psychosom Res. 2007;63:147–156.CrossrefGoogle Scholar 46. Sindhi V, Gupta V, Sharma K, Bhatnagar S, Kumari R, Dhaka N. Potential applications of antioxidants. A review. J Pharm Res. 2013;7:828–835.Google Scholar 47. Kamat CD, Gadal S, Mhatre M, Williamson KS, Pye QN, Hensley K. Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J Alzheimers Dis. 2008;15:473–493.CrossrefGoogle Scholar 48. Li X, Deng J, Shen S, Li T, Yuan M, Yang R, et al. Antioxidant activities and functional properties of enzymatic protein hydrolysates from defatted Camellia oleifera seed cake. J Food Sci Technol. 2015;52:5681–5690.CrossrefGoogle Scholar 49. Mut-Salud N, Álvarez PJ, Garrido JM, Carrasco E, Aránega A, Rodríguez-Serrano F. Antioxidant intake and antitumor therapy: toward nutritional recommendations for optimal results. Oxid Med Cell Longev. 2016;6719534.Google Scholar 50. Foyet HS, Hritcu L, Ciobica A, Stefan M, Kamtchouing P, Cojocaru D. Methanolic extract of Hibiscus asper leaves improves spatial memory deficits in the 6-hydroxydopamine-lesion rodent model of Parkinson’s disease. J Ethnopharmacol. 2011;133:773–779.CrossrefGoogle Scholar 51. Hritcu L, Ciobica A, Artenie V. Effects of right-unilateral 6-hydroxydopamine infusion-induced memory impairment and oxidative stress: relevance for Parkinson’s disease. Cent Eur J Biol. 2008;3:250–257.Google Scholar 52. Foyet HS, Tsala DE, Bouba AA, Hritcu L. Anxiolytic and antidepressant-like effects of the aqueous extract of Alafia multiflora stem barks in rodents. Adv Pharmacol Sci 2012 . ID 912041.Google Scholar 53. Foyet HS, Ngatanko Abaïssou HH, Wado E, Asongalem Acha E, Ciobica A. Emilia coccinea (SIMS) G extract improves memory impairment, cholinergic dysfunction, and oxidative stress damage in scopolamine-treated rats. BMC Complement Altern Med. 2015;15:333.CrossrefGoogle Scholar 54. Crupi R, Mazzon E, Marino A, La Spada G, Bramanti P, Battaglia F, et al. Hypericum perforatum treatment: effect on behaviour and neurogenesis in a chronic stress model in mice. BMC Complement Altern Med. 2011;11:7.CrossrefGoogle Scholar 55. Moshiri E, Basti AA, Noorbala AA, Jamshidi AH, Hesameddin Abbasi S, Akhondzadeh S. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. Phytomedicine. 2006;13:607–611.CrossrefGoogle Scholar 56. Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol. 2011;21:841–860.CrossrefGoogle Scholar 57. Pereira RP, Fachinetto R, De Souza Prestes A, Puntel RL, Santos Da Silva GN, Heinzmann BM, et al. Antioxidant effects of different extracts from Melissa officinalis, Matricaria recutita and Cymbopogon citratus. Neurochem Res. 2009;34:973–983.CrossrefGoogle Scholar 58. Singh V, Singh PS, Chan K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. Int J Neuropsychopharmacol. 2010;13:257–271.CrossrefGoogle Scholar 59. Lohani M, Ahuja M, Buabeid MA, Dean S, Dennis S, Suppiramaniam V, et al. Anti-oxidative and DNA protecting effects of flavonoids-rich Scutellaria lateriflora. Nat Prod Commun. 2013;8:1415–1418.Google Scholar 60. Sayyah M, Boostani H, Pakseresht S, Malayeri A. Comparison of Silybum marianum (L) Gertn with fluoxetine in the treatment of obsessive-compulsive disorder. Prog Neuro-Psychopharmacol Biol Psych. 2010;34:362–365.CrossrefGoogle Scholar 61. Herman H, Pilat L, Mihali C, Popescu C, Turcus V, Ardelean A, et al. Pharmacology of Silybum marianum and its active constituents. Therapeutic activity – Part 2. Arad Med J. 2011;14:35–40.Google Scholar 62. Elsas SM, Rossi DJ, Raber J, White G, Seeley CA, Gregory WL, et al. Passiflora incarnata L. (Passion flower) extracts elicit GABA currents in hippocampal neurons in vitro, and show anxiogenic and anticonvulsant effects in vivo, varying with extraction method. Phytomedicine. 2010;17:940–949.CrossrefGoogle Scholar 63. Chen Y, Han T, Qin L, Rui Y, Zheng H. Effect of total triterpenes from Centella asiatica on the depression behavior and concentration of amino acid in forced swimming mice. Zhong Yao Cai. 2003;26:870–873.Google Scholar 64. Sepand MR, Soodi M, Hajimehdipoor H, Soleimani H, Sahraei E. Comparison of neuroprotective effects of Melissa officinalis total extract and its acidic and non-acidic fractions against A β-induced toxicity. Iran J Pharmacol Res. 2013;12:415–423.Google Scholar 65. Ranjbar A, Khorami S, Safarabadi M, Shahmoradi A, Malekirad AA, Vakilian K, et al. Antioxidant activity of Iranian Echium amoenum fisch & C.A. Mey flower decoction in humans: a cross-sectional before/after clinical trial. Evid Based Complement Alternat Med. 2006;3:469–473.Google Scholar 66. Joshi YB, Praticò D. Lipid peroxidation in psychiatric illness: overview of clinical evidence. Oxid Med Cell Longev 2014 . ID 828702.Google Scholar 67. Erdem M, Akarsu S, Pan E, Kurt YG. Bipolar disorder and oxidative stress. Jmood. 2014;4:70–79.CrossrefGoogle Scholar 68. Liu T, Zhong S, Liao X, Chen J, He T, et al. A meta-analysis of oxidative stress markers in depression. Plos One. 2015;10:0138904.Google Scholar 69. Thomas SP, Nandhra HS, Jayaraman A. Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD). J Ment Health. 2010;19:168–175.CrossrefGoogle Scholar 70. Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs. 2013;27:135–153.CrossrefGoogle Scholar 71. Takeda H, Tsuji M, Inazu M, Egashira T, Matsumiya T. Rosmarinic acid and caffeic acid produce antidepressive-like effect in the forced swimming test in mice. Eur J Pharmacol. 2002;449:261–267.CrossrefGoogle Scholar 72. Hritcu L, Foyet HS, Stefan M, Mihasan M, Asongalem AE, Kamtchouing P. Neuroprotective effect of the methanolic extract of Hibiscus asper leaves in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. J Ethnopharmacol. 2011;137:585–591.CrossrefGoogle Scholar 73. Oboh G, Rocha JBT. Antioxidant and neuroprotective properties of sour tea (Hibiscus sabdariffa, calyx) and green tea (Camellia sinensis) on some pro-oxidant-induced lipid peroxidation in brain in vitro. Food Biophys. 2008;3:382–389.CrossrefGoogle Scholar 74. Nade VS, Kanhere SV, Kawale LA, Yadav AV. Cognitive enhancing and antioxidant activity of ethyl acetate soluble fraction of the methanol extract of Hibiscus rosa sinensis in scopolamine induced amnesia. Indian Pharmacol. 2011;43:137–142.CrossrefGoogle Scholar 75. Foyet HS, Tsala DE, Ngatanko AH. Enhancing spatial memory: anxiolytic and antidepressant effects of Tapinanthus dodoneifolius (DC) Danser in mice. Neurol Res Int. 2014;974308.Google Scholar 76. Hritcu L, Noumedem JA, Cioanca O, Hancianu M, Postu P, Mihasan M. Anxiolytic and antidepressant profile of the methanolic extract of Piper nigrum fruits in beta-amyloid (1-42) rat model of Alzheimer’s disease. Behav Brain Funct. 2015;11:13.CrossrefGoogle Scholar 77. Hritcu L, Cioanca O, Hancianu M. Effects of lavender oil inhalation on improving scopolamine-induced spatial memory impairment in laboratory rats. Phytomedicine. 2012;19:529–534.CrossrefGoogle Scholar 78. Cioanca O, Hritcu L, Mihasan M, Trifan A, Hancianu M. Inhalation of coriander volatile oil increased anxiolytic-antidepressant-like behaviors and decreased oxidative status in beta-amyloid (1-42) rat model of Alzheimer’s disease. Physiol Behav. 2014;131:68–74.CrossrefGoogle Scholar 79. Tsala DE, Theophile D, Judith N, Ng N, Penlap BV, Boda M, et al. Screening of Alafia multiflora for antibacterial, antiradical activity and LD50 investigation. Int J Pharmacol. 2007;3:327–333.CrossrefGoogle Scholar 80. Halliwell B. Reactive species and antioxidants. redox biology is a fundamental theme of aerobic life. Plant Physiol. 2006;141:312–322.CrossrefGoogle Scholar 81. Berk M, Ng F, Dean O, Dodd S, Bush AI. Glutahione: a novel treatment target in psychiatry. Trends Pharmacol Sci. 2008;29:346–351.CrossrefGoogle Scholar 82. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008;11:1–26.CrossrefGoogle Scholar 83. Pillai A. Brain-derived neurotrophic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia. Neurosignals. 2008;16:183–193.CrossrefGoogle Scholar 84. Nemeroff CB, Goldschmidt-Clermont PJ. Heartache and heartbreak-the link between depression and cardiovascular disease. Nat Rev Cardiol. 2012;9:526–539.CrossrefGoogle Scholar 85. Foyet HS, Abdou BA, Ngatanko AH, Manyi FL, Manyo NA, Shu NPN, et al. Neuroprotective and memory improvement effects of a standardized extract of Emilia coccinea (SIMS) G on animal models of anxiety and depression. J Pharmacogn Phytochem. 2014;3:146–154.Google Scholar Received: 2016-06-19 Accepted: 2017-01-24 Published Online: 2017-03-09 Published in Print: 2017-03-08 Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. Research funding: Ioana-Miruna Balmus was co-funded by the European Social Fund through Sectorial Operational Program of Human Resources Development 2007 – 2013, project number POSDRU/187/1.5/S/155397, project title “Towards a New Generation of Elite Researchers through Doctoral Scholarships” during the work for this review. Ciobica Alin and Miruna Balmus are supported by a PN II Research Grant no. PN-II-RU-TE-2014-4-1886, called “A Complex Study regarding the Relevance of Oxytocin Administration in Some Animal Models of Neuropsychiatric Disorders.” Employment or leadership: None declared. Honorarium: None declared. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication. Citation Information: Journal of Complementary and Integrative Medicine, Volume 14, Issue 2, 20160059, ISSN (Online) 1553-3840, DOI: Export Citation © 2017 Walter de Gruyter GmbH, Berlin/Bosto